SCHEMBL29746729

SCHEMBL29746729

CCc1cccc(CC(=O)Nc2ccc(-c3cn(C)c4ncnc(N)c34)c(C)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 9/20 0.53
▸ EIF2AK3 Q9NZJ5 8/20 0.46
▸ AURKB Q96GD4 3/20 0.45
▸ KDR P35968 3/20 0.45
▸ AURKA O14965 2/20 0.45
▸ EIF2AK2 P19525 3/20 0.44
▸ EIF2AK1 Q9BQI3 3/20 0.44
▸ NTRK1 P04629 2/20 0.44
▸ LCK P06239 2/20 0.44
▸ RET P07949 2/20 0.44
▸ AXL P30530 2/20 0.44
▸ NEK4 P51957 2/20 0.44
▸ NTRK2 Q16620 2/20 0.44
▸ MAP4K5 Q9Y4K4 2/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ CYP2C9 P11712 2/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ YES1 P07947 1/20 0.44
▸ CYP2C8 P10632 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043888 1.00 RIPK1 (0.53) RIPK1EIF2AK3AURKBKDRAURKA
SCHEMBL23044652 0.93 EIF2AK3 (0.54) RIPK1EIF2AK3AURKBKDRAURKA
SCHEMBL29746861 0.93 EIF2AK3 (0.54) RIPK1EIF2AK3AURKBKDRAURKA
SCHEMBL29746633 0.93 EIF2AK3 (0.46) RIPK1EIF2AK3NTRK1AXLNTRK2
SCHEMBL23043982 0.93 EIF2AK3 (0.46) RIPK1EIF2AK3NTRK1AXLNTRK2
SCHEMBL23044049 0.92 EIF2AK3 (0.51) RIPK1EIF2AK3KDRNTRK1AXL
SCHEMBL29746539 0.92 EIF2AK3 (0.51) RIPK1EIF2AK3KDRNTRK1AXL
SCHEMBL23043859 0.91 EIF2AK3 (0.54) RIPK1EIF2AK3AURKBKDRAURKA
SCHEMBL23044093 0.91 EIF2AK3 (0.54) RIPK1EIF2AK3AURKBKDREIF2AK2
SCHEMBL29746859 0.91 EIF2AK3 (0.54) RIPK1EIF2AK3AURKBKDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP claimed
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS HIBERCELL, INC. 2022-11-10 — — US disclosed
EP-4021908-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS Hibercell, Inc. (US) 2022-07-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356186-A1 PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS EEF2K, ATF4, MAPKAPK2 RIPK1 451/4885EIF2AK3 96/4885AURKB 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback